Experimental evolution of cefiderocol resistance in Pseudomonas aeruginosa
Cefiderocol is a novel and promising cephalosporin approved for treating severe infections caused by Gram-negative bacteria with limited therapeutic options. One of the primary targets of cefiderocol is Pseudomonas aeruginosa, a significant opportunistic Gram-negative pathogen. In this study, we uti...
שמור ב:
| Principais autores: | , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Elsevier
2025-08-01
|
| סדרה: | Heliyon |
| נושאים: | |
| גישה מקוונת: | http://www.sciencedirect.com/science/article/pii/S2405844025020675 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|